MindMaze Therapeutics Holding SA engages in the development of AI-powered neurotherapeutics and pharmacological treatments for brain disorders. It focuses on addressing neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions. The company is headquartered in Geneva, Switzerland.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. MindMaze Therapeutics Holding SA market cap is $28.68M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. MindMaze Therapeutics Holding SA 52 week high is $3.78 as of November 16, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. MindMaze Therapeutics Holding SA 52 week low is $0.13 as of November 16, 2026.
MindMaze Therapeutics Holding SA stock price today is $0.1687.
MindMaze Therapeutics Holding SA stock price yesterday was $0.1824.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. MindMaze Therapeutics Holding SA's P/E ratio is -0.11.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. MindMaze Therapeutics Holding SA P/B ratio is 0.6438.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. MindMaze Therapeutics Holding SA 50-day moving average is $0.1893.